Zhenhua Xing1, Liang Tang1, Jian Chen1, Junyu Pei1, Pengfei Chen1, Zhenfei Fang1, Shenghua Zhou1, Xinqun Hu2. 1. Departments of Cardiovascular Medicine (Xing, Tang, Pei, Chen, Fang, Zhou, Hu) and Emergency Medicine (Xing), The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; University of South China (Chen), Hengyang, China. 2. Departments of Cardiovascular Medicine (Xing, Tang, Pei, Chen, Fang, Zhou, Hu) and Emergency Medicine (Xing), The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; University of South China (Chen), Hengyang, China huxinqun@csu.edu.cn.
Abstract
BACKGROUND: Previous studies have found that predicted fat mass and lean body mass may act differently on adverse events. However, the cardiovascular prognostic value of lean body mass and fat mass in patients with type 2 diabetes mellitus (T2DM) has not yet been investigated. We sought to investigate the relation between predicted lean body mass or fat mass and the risk of cardiovascular disease in patients with T2DM. METHODS: We conducted a post hoc analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to investigate the relation between the predicted lean body mass or fat mass and major adverse cardiovascular events in patients with T2DM. We used sex-specific quartiles of predicted lean body mass index (BMI; kg/m2) and fat mass index (kg/m2). We defined a major adverse cardiovascular event as a composite of nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes. RESULTS: After a mean follow-up period of 8.8 years, we found that a major cardiovascular event occurred in 1801 of 10 251 patients (17.8%). Predicted lean BMI was not associated with major cardiovascular events (p = 0.34). Compared with patients in the first quartile (incidence rate 16.4%; 17.2%, 17.5% and 19.8% for the second, third and four quartiles, respectively) of predicted fat mass index, those in the fourth quartile had a hazard ratio of 1.53 (95% confidence interval 1.23-1.91). INTERPRETATION: In patients with T2DM, we found that predicted fat mass had a strong positive association with a higher risk of a major adverse cardiovascular event. Increasing lean body mass did not have a protective role. Trial registration: ClinicalTrials.gov., no. NCT00000620.
BACKGROUND: Previous studies have found that predicted fat mass and lean body mass may act differently on adverse events. However, the cardiovascular prognostic value of lean body mass and fat mass in patients with type 2 diabetes mellitus (T2DM) has not yet been investigated. We sought to investigate the relation between predicted lean body mass or fat mass and the risk of cardiovascular disease in patients with T2DM. METHODS: We conducted a post hoc analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to investigate the relation between the predicted lean body mass or fat mass and major adverse cardiovascular events in patients with T2DM. We used sex-specific quartiles of predicted lean body mass index (BMI; kg/m2) and fat mass index (kg/m2). We defined a major adverse cardiovascular event as a composite of nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes. RESULTS: After a mean follow-up period of 8.8 years, we found that a major cardiovascular event occurred in 1801 of 10 251 patients (17.8%). Predicted lean BMI was not associated with major cardiovascular events (p = 0.34). Compared with patients in the first quartile (incidence rate 16.4%; 17.2%, 17.5% and 19.8% for the second, third and four quartiles, respectively) of predicted fat mass index, those in the fourth quartile had a hazard ratio of 1.53 (95% confidence interval 1.23-1.91). INTERPRETATION: In patients with T2DM, we found that predicted fat mass had a strong positive association with a higher risk of a major adverse cardiovascular event. Increasing lean body mass did not have a protective role. Trial registration: ClinicalTrials.gov., no. NCT00000620.
Authors: Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: John B Buse; J Thomas Bigger; Robert P Byington; Lawton S Cooper; William C Cushman; William T Friedewald; Saul Genuth; Hertzel C Gerstein; Henry N Ginsberg; David C Goff; Richard H Grimm; Karen L Margolis; Jeffrey L Probstfield; Denise G Simons-Morton; Mark D Sullivan Journal: Am J Cardiol Date: 2007-04-16 Impact factor: 2.778
Authors: Song-Yi Park; Neal D Freedman; Christopher A Haiman; Loïc Le Marchand; Lynne R Wilkens; Veronica Wendy Setiawan Journal: Ann Intern Med Date: 2017-07-11 Impact factor: 25.391
Authors: Jose R Medina-Inojosa; Virend K Somers; Randal J Thomas; Nathalie Jean; Sarah M Jenkins; Miguel Angel Gomez-Ibarra; Marta Supervia; Francisco Lopez-Jimenez Journal: J Am Heart Assoc Date: 2018-05-08 Impact factor: 5.501
Authors: Gregory A Roth; Catherine O Johnson; Kalkidan Hassen Abate; Foad Abd-Allah; Muktar Ahmed; Khurshid Alam; Tahiya Alam; Nelson Alvis-Guzman; Hossein Ansari; Johan Ärnlöv; Tesfay Mehari Atey; Ashish Awasthi; Tadesse Awoke; Aleksandra Barac; Till Bärnighausen; Neeraj Bedi; Derrick Bennett; Isabela Bensenor; Sibhatu Biadgilign; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Kairat Davletov; Samath Dharmaratne; Eric L Ding; Manisha Dubey; Emerito Jose Aquino Faraon; Talha Farid; Maryam S Farvid; Valery Feigin; João Fernandes; Joseph Frostad; Alemseged Gebru; Johanna M Geleijnse; Philimon Nyakauru Gona; Max Griswold; Gessessew Bugssa Hailu; Graeme J Hankey; Hamid Yimam Hassen; Rasmus Havmoeller; Simon Hay; Susan R Heckbert; Caleb Mackay Salpeter Irvine; Spencer Lewis James; Dube Jara; Amir Kasaeian; Abdur Rahman Khan; Sahil Khera; Abdullah T Khoja; Jagdish Khubchandani; Daniel Kim; Dhaval Kolte; Dharmesh Lal; Anders Larsson; Shai Linn; Paulo A Lotufo; Hassan Magdy Abd El Razek; Mohsen Mazidi; Toni Meier; Walter Mendoza; George A Mensah; Atte Meretoja; Haftay Berhane Mezgebe; Erkin Mirrakhimov; Shafiu Mohammed; Andrew Edward Moran; Grant Nguyen; Minh Nguyen; Kanyin Liane Ong; Mayowa Owolabi; Martin Pletcher; Farshad Pourmalek; Caroline A Purcell; Mostafa Qorbani; Mahfuzar Rahman; Rajesh Kumar Rai; Usha Ram; Marissa Bettay Reitsma; Andre M N Renzaho; Maria Jesus Rios-Blancas; Saeid Safiri; Joshua A Salomon; Benn Sartorius; Sadaf Ghajarieh Sepanlou; Masood Ali Shaikh; Diego Silva; Saverio Stranges; Rafael Tabarés-Seisdedos; Niguse Tadele Atnafu; J S Thakur; Roman Topor-Madry; Thomas Truelsen; E Murat Tuzcu; Stefanos Tyrovolas; Kingsley Nnanna Ukwaja; Tommi Vasankari; Vasiliy Vlassov; Stein Emil Vollset; Tolassa Wakayo; Robert Weintraub; Charles Wolfe; Abdulhalik Workicho; Gelin Xu; Simon Yadgir; Yuichiro Yano; Paul Yip; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Ben Zipkin; Ashkan Afshin; Emmanuela Gakidou; Stephen S Lim; Ali H Mokdad; Mohsen Naghavi; Theo Vos; Christopher J L Murray Journal: JAMA Cardiol Date: 2018-05-01 Impact factor: 14.676
Authors: Yang Zhou; Xiangping Chai; Tuo Guo; Yuting Pu; Mengping Zeng; Aifang Zhong; Guifang Yang; Jiajia Cai Journal: Front Public Health Date: 2022-06-23